Myositis Serum

Human Myositis Serum for Autoimmune Myopathy and Autoantibody Research

Our Myositis Serum is sourced from IRB-consented donors clinically diagnosed with an idiopathic inflammatory myopathy. Each sample is processed and frozen within 24 hours of collection to preserve myositis-specific autoantibodies, muscle enzymes, and inflammatory proteins for autoimmune stratification research.

Why Serum for Myositis Research

The idiopathic inflammatory myopathies are systemic autoimmune diseases, and myositis is unusual in that serology does more than confirm the diagnosis — the autoantibody largely defines the clinical subset. Serum, collected without anticoagulant, is the reference matrix for both the autoantibody profile and the muscle-injury enzymes.

• Myositis-specific autoantibodies define clinical phenotypes — they are mutually exclusive in most donors and map onto distinct organ-involvement patterns, treatment responses, and outcomes, making serotype the most useful stratification variable in the disease
• Dermatomyositis-associated specificities — anti-Mi-2, anti-TIF1γ, anti-NXP2, anti-SAE, and anti-MDA5, the last strongly associated with rapidly progressive interstitial lung disease and often with minimal muscle involvement
• Antisynthetase syndrome — anti-Jo-1 and the non-Jo-1 antisynthetase antibodies define a syndrome combining myositis, interstitial lung disease, and arthritis rather than isolated muscle disease
• Immune-mediated necrotising myopathy — anti-HMGCR, including statin-associated cases, and anti-SRP identify a subset with high creatine kinase and prominent necrosis on biopsy
• Inclusion body myositis — anti-cN1A reactivity is associated with this subtype, which differs mechanistically from the other myopathies and is important to separate in cohort design
• Muscle enzymes and inflammatory proteins in the same sample — creatine kinase and aldolase track muscle injury, while myositis-associated antibodies such as anti-Ro52 and cytokine profiles including a type I interferon signature in dermatomyositis add mechanistic depth

Donor Stratification Available

• Autoantibody serotype — myositis-specific and myositis-associated antibody results reported per lot where measured
• Clinical subtype — dermatomyositis, polymyositis, antisynthetase syndrome, immune-mediated necrotising myopathy, or inclusion body myositis
• Muscle enzyme level — creatine kinase where recorded
• Extramuscular involvement — interstitial lung disease, cutaneous involvement, dysphagia, or arthritis where documented
• Malignancy association — concurrent or recent malignancy where documented
• Treatment status and disease activity — treatment-naive, on corticosteroids or immunosuppressants, on IVIG, or in remission
• Matched healthy controls available — demographically matched healthy donor serum

Product Features

• Collected from clinically confirmed myositis donors
• Processed and frozen within 24 hours of collection
• Research Use Only (RUO)
• Standard and custom aliquot volumes available
• IRB-approved protocols with documented consent

De-identified Donor Data

• Diagnosis confirmation and clinical subtype where classified
• Age, sex assigned at birth, and ethnicity
• Donor-reported allergy, medication, and infectious disease history
• Autoantibody status, enzyme values, and organ involvement available on request

Applications

• Myositis-specific autoantibody detection and multiplex panel development
• Serological subtyping and cohort stratification research
• Creatine kinase and muscle-injury biomarker assay work
• Type I interferon signature measurement in dermatomyositis
• Interstitial lung disease risk biomarker discovery, including anti-MDA5 cohorts
• Cytokine, chemokine, and inflammatory protein profiling
• Treatment response and disease activity biomarker research
• Therapeutic candidate screening and validation

Other Myositis Specimen Types

Matched material from the same myositis donor pool is available as myositis plasma, whole blood, PBMC, and leukopak. Subtype-specific cohorts are available as dermatomyositis serum, polymyositis serum, and inclusion body myositis serum.

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Myositis serum is available in standard and custom volumes. For pricing, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse the full specimen range and healthy-donor controls, see our human serum collection.